Aspen Aerogels, Inc. (NYSE:ASPN) Receives Average Recommendation of “Buy” from Brokerages

Aspen Aerogels, Inc. (NYSE:ASPN) has been given an average recommendation of “Buy” by the ten analysts that are presently covering the firm, Marketbeat reports. Nine equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $29.40.

Several research firms have commented on ASPN. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Aspen Aerogels in a report on Wednesday, October 16th. StockNews.com upgraded shares of Aspen Aerogels to a “sell” rating in a report on Thursday, October 31st. TD Cowen upped their price objective on shares of Aspen Aerogels from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, August 20th. Piper Sandler decreased their price objective on shares of Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Finally, Benchmark reiterated a “buy” rating and issued a $14.00 price objective on shares of Aspen Aerogels in a report on Thursday, August 8th.

Aspen Aerogels Price Performance

Shares of ASPN opened at $18.51 on Wednesday. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -1,851.00 and a beta of 2.21. Aspen Aerogels has a 1-year low of $8.58 and a 1-year high of $33.15. The company’s fifty day simple moving average is $23.82 and its 200 day simple moving average is $24.71. The company has a current ratio of 3.46, a quick ratio of 2.82 and a debt-to-equity ratio of 0.23.

Aspen Aerogels (NYSE:ASPN) last issued its earnings results on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The business had revenue of $117.80 million for the quarter, compared to the consensus estimate of $101.99 million. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The firm’s revenue for the quarter was up 144.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.22) earnings per share. On average, research analysts forecast that Aspen Aerogels will post 0.1 earnings per share for the current fiscal year.

Insider Activity at Aspen Aerogels

In related news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the transaction, the chief executive officer now directly owns 483,640 shares in the company, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the completion of the sale, the chief executive officer now owns 483,640 shares of the company’s stock, valued at $14,523,709.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $30.14, for a total transaction of $978,495.10. Following the sale, the chief financial officer now directly owns 20,790 shares of the company’s stock, valued at $626,610.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aspen Aerogels

Institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Aspen Aerogels by 10.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,310 shares of the construction company’s stock worth $341,000 after acquiring an additional 1,339 shares during the last quarter. nVerses Capital LLC lifted its holdings in shares of Aspen Aerogels by 45.0% in the third quarter. nVerses Capital LLC now owns 5,800 shares of the construction company’s stock worth $161,000 after acquiring an additional 1,800 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Aspen Aerogels by 15.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,580 shares of the construction company’s stock worth $257,000 after acquiring an additional 1,938 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Aspen Aerogels in the second quarter worth about $84,000. Finally, Quent Capital LLC bought a new position in shares of Aspen Aerogels in the third quarter worth about $118,000. Institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.